Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

30, 2025. This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years. It usually doesn't matter if you ...

However, the true winners in the biotech sector find ways to expand their market opportunity by winning the FDA approval for new drugs. Vertex, after securing a dominant position in the CF drug ...

In the preceding three months, 12 analysts have released ratings for Vertex (NASDAQ:VERX), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a ...

ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...